Table 2 The status of metastasis and treatment response related with sampling
|  | HR + (N = 58) | HER2 + (N = 44) | TN (N = 39) | Overall (N = 141) |
|---|---|---|---|---|
Metastasis sites | ||||
 Chest wall | 18 | 8 | 8 | 34 |
 Bone | 35 | 20 | 10 | 65 |
 Lymph node | 36 | 25 | 27 | 88 |
 Lung | 20 | 15 | 15 | 50 |
 Liver | 16 | 16 | 10 | 42 |
 Brain and others | 22 | 6 | 10 | 35 |
Visceral metastasis | ||||
 No | 28 (48.3%) | 21 (47.7%) | 18 (46.2%) | 67 (47.5%) |
 Yes | 30 (51.7%) | 23 (52.3%) | 21 (53.8%) | 74 (52.5%) |
No. of metastasis | ||||
 1 | 10 (17.2%) | 16 (36.4%) | 10 (25.6%) | 36 (25.5%) |
 2 | 22 (37.9%) | 16 (36.4%) | 13 (33.3%) | 51 (36.2%) |
 ≥ 3 | 26 (44.8%) | 11 (25.0%) | 12 (30.8%) | 49 (34.8%) |
 Unknown | 0 (0%) | 1 (2.3%) | 4 (10.3%) | 5 (3.5%) |
Disease status of sampling | ||||
 First-line metastasis | 43 (74.1%) | 32 (72.7%) | 29 (74.3%) | 104 (73.8%) |
 Primary IV | 15 (25.9%) | 12 (27.3%) | 6 (15.4%) | 33 (23.4%) |
 Unknown | 0 (0%) | 0 (0%) | 4 (10.3%) | 4 (2.8%) |
Best response after ctDNA sampling | ||||
 CR/PR | 15 (25.9%) | 22 (50.0%) | 11 (28.2%) | 48 (34.0%) |
 SD | 33 (56.9%) | 12 (27.3%) | 16 (41.0%) | 61 (43.3%) |
 PD | 7 (12.1%) | 6 (13.6%) | 8 (20.5%) | 21 (14.9%) |
 NE | 3 (5.2%) | 4 (9.1%) | 4 (10.3%) | 11 (7.8%) |